About CReATe

The CReATe Consortium, funded by the National Institutes of Health (NIH), is a collaborative research initiative focused on improving our understanding of amyotrophic lateral sclerosis (ALS) and a group of related disorders including frontotemporal dementia (FTD), progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP) and multisystem proteinopathy (MSP). The consortium's primary goal is to accelerate the development of effective treatments for ALS by fostering collaboration among researchers and overcoming roadblocks to therapy development.

The CReATe Consortium was established in 2014 with an initial five-year funding commitment from the NIH's National Institute of Neurological Disorders and Stroke (NINDS) and National Center for Advancing Translational Sciences (NCATS). CReATe was refunded by NIH in 2019. Since its inception, the Consortium has grown to include multiple academic institutions, clinical centers, patient advocacy groups, and industry partners working together to advance ALS research. The consortium's research efforts encompass various aspects of ALS and related disorders, including deep phenotyping, genomics, biomarkers, imaging, clinical trials, and disease mechanisms.

One of the main strengths of the CReATe Consortium is its emphasis on collaboration. By bringing together leading experts in ALS research, the consortium facilitates the sharing of knowledge, data, and resources to accelerate scientific discovery. This collaborative approach enables researchers to tackle complex questions about ALS from multiple angles, leveraging diverse expertise and perspectives. In addition to its research activities, the CReATe Consortium is dedicated to training and supporting the next generation of ALS researchers. It provides educational opportunities, mentorship programs, and resources for early-career scientists interested in ALS research. By nurturing young talent, the Consortium aims to sustain a vibrant research community focused on advancing our understanding of ALS and developing effective therapies.